Ainos (NASDAQ:AIMD) Posts Quarterly Earnings Results

Ainos (NASDAQ:AIMD) posted its quarterly earnings data on Monday. The company reported ($0.62) EPS for the quarter, FiscalAI reports. Ainos had a negative net margin of 11,912.10% and a negative return on equity of 160.55%.

Ainos Stock Up 9.0%

NASDAQ AIMD traded up $0.12 during trading hours on Monday, hitting $1.45. 28,514 shares of the company were exchanged, compared to its average volume of 431,189. The company has a 50 day moving average of $1.88 and a two-hundred day moving average of $1.74. The company has a quick ratio of 0.50, a current ratio of 0.55 and a debt-to-equity ratio of 1.58. Ainos has a 52-week low of $1.26 and a 52-week high of $4.50. The firm has a market cap of $12.36 million, a price-to-earnings ratio of -0.50 and a beta of 2.43.

Insider Buying and Selling at Ainos

In other news, major shareholder Carbon Nano Technology Taiwan sold 41,000 shares of Ainos stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $2.36, for a total value of $96,760.00. Following the completion of the transaction, the insider owned 948,925 shares in the company, valued at approximately $2,239,463. This trade represents a 4.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Ting-Chuan Lee sold 109,988 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total value of $208,977.20. Following the transaction, the director directly owned 807,417 shares of the company’s stock, valued at approximately $1,534,092.30. This represents a 11.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have purchased 7,500 shares of company stock valued at $15,435 and have sold 179,788 shares valued at $359,247. 9.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. DRW Securities LLC raised its holdings in shares of Ainos by 272.6% in the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock valued at $109,000 after purchasing an additional 48,439 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of Ainos during the third quarter worth $80,000. Mariner LLC purchased a new position in Ainos in the fourth quarter valued at $37,000. Finally, Renaissance Technologies LLC raised its stake in Ainos by 13.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares in the last quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has a consensus rating of “Sell”.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.